Key Drivers
- Strong Cash Flow
- High Intangibles
- Premium Valuation
AIAI Summary
COO is no longer just a steady healthcare compounder; with strong free cash flow and improving margins, the stock's rerating now hinges on proving broader organic growth—especially in Asia Pacific and CooperSurgical—because until execution becomes more consistent, valuation upside is capped by credibility and regional recovery risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •High Intangibles
- •Premium Valuation
CooperCompanies has solid and improving margins with strong cash flow and manageable leverage, but modest capital returns, an intangible-heavy balance sheet, and a full valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Bounce risk
COO has been in a clear bearish downtrend over the last month, trading near oversold support around $59-$60 with only a possible bounce unless it reclaims $61-$65.
Brief rebound from $58.98 on 2026-05-11 to $60.38 on 2026-05-14 before fading again
Sentiment & News
Key News Insights:
- •Growth spotlight
- •Valuation focus
- •Board update
COO is attracting continued investor attention as both a growth and value candidate, supported by favorable stock coverage, a new board appointment, and a modest portfolio trim.
Overall, the news flow is mildly positive and should keep COO on investors' radar, though the main catalyst remains relative valuation versus peers
Similar Companies in Healthcare
Other companies in the same sector with AI ratings